GlaxoSmithKline Pays €45 M Upfront to Access Immatics’ Cell Therapy Platform
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 2 (Table of Contents)
Published: 25 Feb-2020
DOI: 10.3833/pdr.v2020.i2.2514 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Broadening its cell therapy pipeline, GlaxoSmithKline has agreed to partner with Immatics Biotechnologies to develop T-cell receptor therapies for the treatment of cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS